[{"id":"ea39bf9b-3a98-46eb-8bfc-59230c1a4e1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05395780","created_at":"2022-05-27T11:56:31.465Z","updated_at":"2024-07-02T16:36:09.466Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05395780","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-06-02"},{"id":"c7c7b388-a345-4c9d-9046-42dc16d8c6a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05369286","created_at":"2022-05-11T16:55:50.518Z","updated_at":"2024-07-02T16:36:10.590Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05369286","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2022-05-11"},{"id":"b185f5af-b20b-432d-b8f0-d2a61b2a09b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03412292","created_at":"2021-01-18T16:50:05.305Z","updated_at":"2024-07-02T16:36:18.334Z","phase":"Phase 1","brief_title":"MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)","source_id_and_acronym":"NCT03412292","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FLT3 • FGFR","pipe":" | ","alterations":" FLT3 wild-type","tags":["FLT3 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-01-19"},{"id":"910f01e8-e129-4f75-9739-81c5fb413c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05130021","created_at":"2021-11-22T14:53:41.790Z","updated_at":"2024-07-02T16:36:19.855Z","phase":"Phase 2","brief_title":"A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT05130021","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • RAS wild-type","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Max-40279"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 05/30/2022","primary_completion_date":" 05/30/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2021-12-06"}]